modernretina.com

Evaluation du site modernretina.com

Modern Retina – Ophthalmology News, Events & Expert Insights

 Généré le 31 Mars 2026 15:12

Vieilles statistiques? UPDATE !

Le score est de 57/100

Optimisation du contenu

Titre

Modern Retina – Ophthalmology News, Events & Expert Insights

Longueur : 60

Parfait, votre titre contient entre 10 et 70 caractères.

Description

Modern Retina provides ophthalmology professionals with the latest advancements, research, and expert insights in retinal care to improve patient outcomes.

Longueur : 155

Génial, votre balise META description contient entre 70 et 160 caractères.

Mots-clefs

Très mauvais. Nous n'avons pas trouvé de balise META keywords sur votre page. Utilisez ce générateur gratuit de balises META en ligne pour créer des mots-clés.

Propriétés Open Graph

Bien, cette page profite des balises META Open Graph.

Propriété Contenu
title Modern Retina
type website
image https://www.modernretina.com/MR_Hover_Logo.jpg
url https://www.modernretina.com/
image:url https://www.modernretina.com/MR_Hover_Logo.jpg
image:width 1200
image:height 630
image:alt Modern Retina – Ophthalmology News, Events & Expert Insights

Niveaux de titre

H1 H2 H3 H4 H5 H6
1 56 46 4 16 0
  • [H1] Latest News
  • [H2] Conference Coverage
  • [H2] Trending on Modern Retina
  • [H2] Shorts
  • [H2] Podcasts
  • [H2] Videos
  • [H2] Modern Retina Digital Edition
  • [H2] Continuing Medical Education
  • [H2] (CME Track) Revolutionizing nAMD and DME Management: Collaborative Strategies in the Age of Durable Treatments
  • [H2] (CME Track) Expanding Horizons in Toric IOLs: Translating Technological Advances Into Improved Patient Outcomes
  • [H2] (CME Track) The Neural Frontier: Mapping Neurostimulation Across the DED Patient Spectrum for Refractive Surgery
  • [H2] (COPE Credit) Time Matters in GA: The Impact of Early Detection and Proactive Treatment Approaches
  • [H2] (CME Track) Visionary Approaches: Rethinking Therapeutic and Interventional Glaucoma Management
  • [H2] (CME Credit) Time Matters in GA: The Impact of Early Detection and Proactive Treatment Approaches
  • [H2] (CME Track) The TED Perspective: A Multidisciplinary Approach to Thyroid Eye Care
  • [H2] (COPE Track) Patient-Centered Treatment Strategies in the Management of nAMD and DME
  • [H2] (CME Track) Patient-Centered Treatment Strategies in the Management of nAMD and DME
  • [H2] Practical Approaches to Modern Dry Eye Treatment and Management
  • [H2] (COPE Track) Visionary Approaches: Rethinking Therapeutic and Interventional Glaucoma Management
  • [H2] (COPE Track) Revolutionizing nAMD and DME Management: Collaborative Strategies in the Age of Durable Treatments
  • [H2] (COPE Track) Expanding Horizons in Toric IOLs: Translating Technological Advances Into Improved Patient Outcomes
  • [H2] (COPE Track) The TED Perspective: A Multidisciplinary Approach to Thyroid Eye Care
  • [H2] (COPE Track) The Neural Frontier: Mapping Neurostimulation Across the DED Patient Spectrum for Refractive Surgery
  • [H2] 20th Annual Controversies in Modern Eye Care
  • [H2] (CME Track) Clinical Consultations™: Framing a New Approach to Geographic Atrophy Management – Expert Insights into Recent Developments
  • [H2] (COPE Track) Clinical Consultations™: Framing a New Approach to Geographic Atrophy Management – Expert Insights into Recent Developments
  • [H2] (CME Track) Rapid Reviews in Retina™: Emerging Updates from Winter 2025 – Addressing the Wealth of New Data in Treatments for nAMD and DME
  • [H2] (COPE Track) Rapid Reviews in Retina™: Emerging Updates from Winter 2025 – Addressing the Wealth of New Data in Treatments for nAMD and DME
  • [H2] Living With X-Linked Retinitis Pigmentosa: What We Can Learn From a Patient’s Experience
  • [H2] (CME Track) Collaborative Community Connections™: Mastering the Management of nAMD and DME Through Therapeutic Innovation
  • [H2] Living With X-Linked Retinitis Pigmentosa: What We Can Learn From a Patient’s Experience
  • [H2] (COPE Track) Collaborative Community Connections™: Mastering the Management of nAMD and DME Through Therapeutic Innovation
  • [H2] Collaborative Care Symposium
  • [H2] Navigating the Glaucoma Therapeutic and Surgical Landscape: From Conventional to Cutting-Edge
  • [H2] (CME Track) Neurotrophic Keratitis: Multidisciplinary Approaches to Enhance Patient Outcomes
  • [H2] (COPE Track) Neurotrophic Keratitis: Multidisciplinary Approaches to Enhance Patient Outcomes
  • [H2] (CME Track) The Neural Network: Exploring The Role of Neuromodulation in Dry Eye Disease Management
  • [H2] (COPE Track) The Neural Network: Exploring The Role of Neuromodulation in Dry Eye Disease Management
  • [H2] (CME Track) Toric IOLs Unleashed: From Technological Progress to Patient Success
  • [H2] (COPE Track) Clinical Case Connections: Understanding the Impact of Advances in Treatment for DME and DR
  • [H2] (COPE Track) Toric IOLs Unleashed: From Technological Progress to Patient Success
  • [H2] (COPE Track) Clinical Case Connections: Expert Insights on Applying Therapeutic Innovations in nAMD
  • [H2] (CME Track) Clinical Case Connections: Expert Insights on Applying Therapeutic Innovations in nAMD
  • [H2] (CME Track) Clinical Case Connections: Understanding the Impact of Advances in Treatment for DME and DR
  • [H2] Neurotrophic Keratitis Insights: An Interactive Corneal Sensitivity Testing Workshop
  • [H2] (COPE Credit) Navigating Pharmacological Presbyopia Treatment for Enhanced Patient Care
  • [H2] (COPE Track) Small Mites, Big Impact: Revolutionizing Demodex Blepharitis Care
  • [H2] (CME Credit) Navigating Pharmacological Presbyopia Treatment for Enhanced Patient Care
  • [H2] (CME Track) Small Mites, Big Impact: Revolutionizing Demodex Blepharitis Care
  • [H2] Rapid Reviews in Retina™: Emerging Updates from Spring 2025—Addressing the Wealth of New Data in Treatments for Neovascular Retinal Disease
  • [H2] Interventional Dry Eye: A Stepwise Treatment & Management Approach
  • [H2] (CME Track) Rapid Reviews in Retina™: Emerging Updates from Summer 2025—Addressing the Wealth of New Data in Treatments for Neovascular Retinal Disease
  • [H2] (CME Track) A Forward Look at Anti-VEGF Therapies: A Paradigm Shift in Neovascular Retinal Disease Management
  • [H2] (CME Track) Community Collaborative Connections™: Optimizing the Collaborative Care of Neovascular Retinal Disease in a New Age of Treatment
  • [H2] (CME Track) The Evolution of MacTel Management: Integrating Neuroprotective Therapies Into Clinical Practice
  • [H2] (CME Track) Collaborating Across the Continuum™: Best Practices in Patient-Centric Team Management of XLRP
  • [H2] All News
  • [H3] Aflibercept to treat ROP in extremely-low-birth-weight children
  • [H3] Multi-luminance shape discrimination test shows reliability in low-vision RP population
  • [H3] Aflibercept to treat ROP in extremely-low-birth-weight children
  • [H3] Eichenbaum Acorns: Collaborative retina care with Jeffry D. Gerson, OD, FAAO
  • [H3] Eichenbaum Acorns: Mentorship, momentum, and the making of a retina podcast
  • [H3] Eichenbaum Acorns: Inside the mindset of an early adopter with Jordan M. Graff, MD, FACS
  • [H3] The Retina TL;DR: Redefining office-based surgery for retina care with Jonathan Feistmann, MD
  • [H3] Eichenbaum Acorns: A leadership conversation with Rishi P. Singh, MD, FASRS, on advancing CME
  • [H3] The Retina TL;DR: Rethinking retinal detachment repair with Tony Stefater, MD, PhD; and Tommy Stryjewski, MD
  • [H3] PHOTON Trial Outcomes: Impact on DME Patient Care in Clinical Practice
  • [H3] PULSAR Study Findings: Implications for Treating nAMD in Clinical Practice
  • [H3] Integrating AI to manage DR in a primary care setting
  • [H3] What to expect from virtual AAO 2020
  • [H3] Genetic Retinoblastoma Risk Stratified by Age Among Patients with Metachronous Bilateral Conversion
  • [H3] Galimedix Therapeutics earns milestone payment in ophthalmology partnership with Théa Open Innovation
  • [H3] Ophthalmic drug shortages more frequent, longer lasting than average
  • [H3] Johnson & Johnson’s TECNIS PureSee EDOF IOL cleared for US market
  • [H3] Eichenbaum Acorns: Collaborative retina care with Jeffry D. Gerson, OD, FAAO
  • [H3] NovaBridge, Visara report positive phase 2a results for dual VEGF-A/ANG-2 inhibitor VIS-101
  • [H3] FDA clears phase I/II trial of SVT-001 cell therapy for familial drusen–associated vision loss
  • [H3] Ocugen completes enrollment in liMeliGhT phase 3 trial of OCU400 for retinitis pigmentosa
  • [H3] Pegcetacoplan Does Not Impact Anti-VEGF Treatment in Geographic Atrophy, With Ted Leng, MD, MS
  • [H3] Q&A: AI-predicted retinal function shows promise in geographic atrophy
  • [H3] Dr. Mali’s top 5 predictions in ophthalmology for 2026
  • [H3] The Retina TL;DR with Dr. Weng: Tracking retinal gene therapies with Arshad M. Khanani, MD, MA, FASRS
  • [H3] Q&A: Gennady Landa, MD, shares clinical insights on the ranibizumab ocular implant
  • [H3] Samsung Bioepis reaches settlement agreement for Eylea (aflibercept) biosimilar
  • [H3] ISS 2026 highlights advances in ophthalmic imaging for retinal practice
  • [H3] American College of Physicians policy paper urges medical community to drop the term “'provider"
  • [H3] PRIMA System: A major step in the battle against GA
  • [H3] MeiraGTx Licenses complement-targeted geographic atrophy program from ZipBio
  • [H3] Metformin use associated with reduced incidence of intermediate AMD
  • [H3] FDA decision: Carbachol–brimonidine ophthalmic solution approved for presbyopia following BRIO phase 3 results
  • [H3] New optoretinography technique allows direct measurement of rod function in vivo
  • [H3] Navigating geographic atrophy from biomarkers to bilateral therapy
  • [H3] Ollin Biosciences reports positive head-to-head phase 1b data for OLN324 vs faricimab
  • [H3] Eichenbaum Acorns: Mentorship, momentum, and the making of a retina podcast
  • [H3] Long-lived Greenland sharks may point to new approaches for retinal disease
  • [H3] Molecular insights and clinical experience: Extending anti-VEGF durability
  • [H3] Q&A: Evolving approaches to geographic atrophy management
  • [H3] Nanoscope secures new US patent for Multi-Characteristic Opsin (MCO) technology platform
  • [H3] Rates of retinal layer thinning predict visual field progression in glaucoma
  • [H3] First patient treated in dose-expansion portion of SpliceBio's phase 1/2 ASTRA clinical trial
  • [H3] FDA grants Fast Track Designation to Complement Therapeutics’ CTx001 for geographic atrophy
  • [H3] 8 things to know about aflibercept 8 mg for retinal vascular disease
  • [H3] A new treatment round-up for AMD and GA
  • [H4] Multi-luminance shape discrimination test shows reliability in low-vision RP population
  • [H4] Phase 2 topline data: Ocugen OCU410 reduces geographic atrophy lesion growth by 31% at 12 months
  • [H4] The Retina TL;DR with Dr. Weng: Moving beyond anti-VEGF with OTX-TKI and Pravin U. Dugel, MD
  • [H4] ONL Therapeutics randomizes first European patient in phase 2 GA trial of Xelafaslatide
  • [H5] The Retina TL;DR with Dr. Weng: Moving beyond anti-VEGF with OTX-TKI and Pravin U. Dugel, MD
  • [H5] Pegcetacoplan Does Not Impact Anti-VEGF Treatment in Geographic Atrophy, With Ted Leng, MD, MS
  • [H5] The Retina TL;DR with Dr. Weng: Tracking retinal gene therapies with Arshad M. Khanani, MD, MA, FASRS
  • [H5] Exploring Emerging Therapies in the Retinal Vascular Disease Pipeline
  • [H5] The Retina TL;DR with Dr. Weng: Targeting the Fas signaling pathway with David Zacks, MD, PhD
  • [H5] Evaluating Safety and Clinical Confidence between Aflibercept 8 mg and 2 mg in Retinal Vascular Diseases
  • [H5] Management Approaches for Suboptimal Responders in AMD, DME, and RVO
  • [H5] Comparing Aflibercept 8 mg and Faricimab in RVO
  • [H5] Insights from Privotal Trials for Aflibercept (8 mg) in RVO
  • [H5] Evaluating Retinal Drying, Durability and IOP Management with Second-Generation Anti-VEGF Therapies in Retinal Vascular Diseases
  • [H5] Loading Dose Adjustments and Treatment Switching Strategies in Retinal Vascular Diseases
  • [H5] Enhancing Durability and Fluid Control with Aflibercept 8 mg in Retinal Vascular Diseases
  • [H5] Evolving Therapeutic Strategies with Next-Generation Anti-VEGF Agents in Retinal Vascular Diseases
  • [H5] Clinical Insights Shaping Real-World Decision-Making in Geographic Atrophy
  • [H5] Managing Geographic Atrophy in a 90-Year-Old Patient with Coexisting Neovascular AMD and Recurrent CNV Activation
  • [H5] Evaluating Progressive Multifocal Geographic Atrophy in an Asymptomatic 81-Year-Old Male

Images

Nous avons trouvé 135 image(s) sur cette page Web.

23 attribut(s) alt sont vides ou manquants. Ajouter un texte alternatif permet aux moteurs de recherche de mieux comprendre le contenu de vos images.

Ratio texte/HTML

Ratio : 3%

le ratio de cette page texte/HTML est au-dessous de 15 pour cent, ce qui signifie que votre site manque de contenu textuel.

Flash

Parfait, aucun contenu FLASH n'a été détecté sur cette page.

Iframe

Génial, il n'y a pas d'Iframes détectés sur cette page.

Réécriture d'URLs

Bien. Vos liens sont optimisés!

Tiret bas dans les URLs

Parfait! Aucuns soulignements détectés dans vos URLs.

Liens dans la page

Nous avons trouvé un total de 89 lien(s) dont 0 lien(s) vers des fichiers

Texte d'ancre Type Juice
All News Interne Passing Juice
Blogs Interne Passing Juice
All Videos Interne Passing Juice
Case-Based Roundtable Series Interne Passing Juice
Eichenbaum Acorns Interne Passing Juice
Expert Interviews Interne Passing Juice
Eyeviews Interne Passing Juice
Insights Interne Passing Juice
Medical World News Externe Passing Juice
Podcasts Interne Passing Juice
Rapid Readouts Interne Passing Juice
The Retina TL;DR Interne Passing Juice
Viewpoints Interne Passing Juice
Conference Coverage Interne Passing Juice
Conference Listing Interne Passing Juice
Modern Retina Digital Edition Interne Passing Juice
Supplements And Featured Publications Interne Passing Juice
Between the Lines Interne Passing Juice
CME/CE Interne Passing Juice
EYLEA 8mg for nAMD and DME Treatment Interne Passing Juice
Sponsored Resources Interne Passing Juice
Partners Interne Passing Juice
Subscribe Interne Passing Juice
AMD Interne Passing Juice
Wet AMD Interne Passing Juice
Biosimilar Interne Passing Juice
Diabetic Macular Edema Interne Passing Juice
Diabetic Eye Awareness Interne Passing Juice
Diabetic Retinopathy Interne Passing Juice
Geographic Atrophy Interne Passing Juice
Imaging Interne Passing Juice
Inherited Retinal Diseases Interne Passing Juice
Ophthalmology Interne Passing Juice
RVO Interne Passing Juice
Retina Technology Interne Passing Juice
Retinal Surgery Interne Passing Juice
Uveitis Interne Passing Juice
Geographic Atrophy Interne Passing Juice
ISS 2026 highlights advances in ophthalmic imaging for retinal practice Interne Passing Juice
FLORetina: Inadvertent anti-VEGF interval increases during the COVID-19 pandemic Interne Passing Juice
Treating MacTel: First identify patient candidates and appropriate eye selection Interne Passing Juice
A medical fellow finds some magic at the AAO Annual Meeting Interne Passing Juice
FLORetina 2025: EU-ROP Registry bridges borders for real-world insight Interne Passing Juice
FLORetina 2025: Updates on tinlarebant in adolescent Stargardt disease Interne Passing Juice
FLORetina 2025: Long-term follow-up in pediatric gene therapy Interne Passing Juice
FLORetina 2025: Mary Elizabeth Hartnett on ROP research and risk management Interne Passing Juice
FLORetina 2025: Reframing retinal disease through the lens of choroidal health Interne Passing Juice
FLORetina 2025: Antithrombotic use examined in wet AMD submacular hemorrhage Interne Passing Juice
Martin David Harp Interne Passing Juice
Christina Y. Weng, MD, MBA, FASRS Interne Passing Juice
View All Interne Passing Juice
Eichenbaum Acorns: Collaborative retina care with Jeffry D. Gerson, OD, FAAO Interne Passing Juice
Eichenbaum Acorns: Mentorship, momentum, and the making of a retina podcast Interne Passing Juice
Eichenbaum Acorns: Inside the mindset of an early adopter with Jordan M. Graff, MD, FACS Interne Passing Juice
The Retina TL;DR: Redefining office-based surgery for retina care with Jonathan Feistmann, MD Interne Passing Juice
Eichenbaum Acorns: A leadership conversation with Rishi P. Singh, MD, FASRS, on advancing CME Interne Passing Juice
The Retina TL;DR: Rethinking retinal detachment repair with Tony Stefater, MD, PhD; and Tommy Stryjewski, MD Interne Passing Juice
PHOTON Trial Outcomes: Impact on DME Patient Care in Clinical Practice Interne Passing Juice
PULSAR Study Findings: Implications for Treating nAMD in Clinical Practice Interne Passing Juice
Integrating AI to manage DR in a primary care setting Interne Passing Juice
What to expect from virtual AAO 2020 Interne Passing Juice
View More Interne Passing Juice
Navigating geographic atrophy from biomarkers to bilateral therapy Interne Passing Juice
8 things to know about aflibercept 8 mg for retinal vascular disease Interne Passing Juice
Inside the mindset of an early adopter Interne Passing Juice
Challenges for young physicians treating patients with GA Interne Passing Juice
AAO highlight: Looking ahead to 2026 Interne Passing Juice
How AI is reshaping ophthalmology in 2025 and beyond Interne Passing Juice
Seeing the difference: Multimodal imaging for AMD and GA Interne Passing Juice
Ryan Livingston Interne Passing Juice
Lynda Charters Interne Passing Juice
Kevin Kunzmann Interne Passing Juice
Jeffry D. Gerson, OD, FAAO Interne Passing Juice
Theodore Leng, MD, MS Interne Passing Juice
Sheryl Stevenson Interne Passing Juice
Joshua Mali, MD Interne Passing Juice
Arshad M. Khanani, MD, MA, FASRS Interne Passing Juice
Modern Retina Staff Reports Interne Passing Juice
Jayanth Sridhar, MD Interne Passing Juice
Matt Hoffman Interne Passing Juice
Sheila Setork, OD Interne Passing Juice
About Interne Passing Juice
Advertise Interne Passing Juice
Editorial Interne Passing Juice
Contact Us Interne Passing Juice
Terms and Conditions Interne Passing Juice
Privacy Interne Passing Juice
Do Not Sell My Personal Information Externe Passing Juice
Home Interne Passing Juice

Mots-clefs

Nuage de mots-clefs

video cme management view faao track fasrs more retinal cope

Cohérence des mots-clefs

Mot-clef Contenu Titre Mots-clefs Description Niveaux de titre
more 64
view 52
video 44
track 35
faao 24

Ergonomie

Url

Domaine : modernretina.com

Longueur : 16

Favicon

Génial, votre site web dispose d'un favicon.

Imprimabilité

Aucun style CSS pour optimiser l'impression n'a pu être trouvé.

Langue

Bien. Votre langue est : en.

Dublin Core

Cette page ne profite pas des métadonnées Dublin Core.

Document

Doctype

HTML 5

Encodage

Parfait. Votre charset est UTF-8.

Validité W3C

Erreurs : 0

Avertissements : 0

E-mail confidentialité

Attention! Au moins une adresse e-mail a été trouvée en texte clair. Utilisez une protection anti-spam gratuite pour cacher vos e-mails aux spammeurs.

HTML obsolètes

Génial! Nous n'avons pas trouvé de balises HTML obsolètes dans votre code.

Astuces vitesse

Excellent, votre site n'utilise pas de tableaux imbriqués.
Mauvais, votre site web utilise des styles css inline.
Génial, votre site web contient peu de fichiers CSS.
Mauvais, votre site web contient trop de fichiers javascript (plus de 6).
Parfait : votre site tire parti de gzip.

Mobile

Optimisation mobile

Icône Apple
Méta tags viewport
Contenu FLASH

Optimisation

Sitemap XML

Votre site web dispose d’une sitemap XML, ce qui est optimal.

https://www.modernretina.com/sitemap.xml
https://www.modernretina.com/sitemap-news.xml

Robots.txt

https://modernretina.com/robots.txt

Votre site dispose d’un fichier robots.txt, ce qui est optimal.

Mesures d'audience

Votre site web dispose d’une outil d'analytics, ce qui est optimal.

   Google Analytics

PageSpeed Insights

Dispositif
Les catégories

Free SEO Testing Tool

Free SEO Testing Tool est un outil gratuit de référencement qui vous aidera à analyser vos pages web